ClinicalTrials.gg
RecruitingNCT06852053APNeAUpdated Oct 2, 2026

Application to Predict Neonatal Apnea With Bradycardia

An interventional study of Closed-loop Vibro-Tactile Stimulator and Control in Apnea Neonatal and Bradycardia Neonatal, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 22 Weeks to 32 Weeks. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 2, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
22 Weeks to 32 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 85 studies in Apnea with a site in United States — 15 open to participants now, 18 under way, 2 of them phase 3. Apnea · United States.

Planned enrollment
55th of 69
25 · median 80
Started
2026
with 8 others
No phase
49 of 85
10 open now
Primary completion
2027-12
later than 13 of 17 live
Registered
75th of 85
by date
Lead sponsor
4 of 85
University of Alabama at Birmingham

Among the 85 studies in Apnea with a site in United States, this one is the 55th largest by planned enrollment of the 69 interventional ones that give a count, is one of 9 that started in 2026, is one of 49 with no phase, reaches primary completion later than 13 of the 17 other live ones, and was the 75th registered.

Apnea

283 studies on the registry are indexed under Apnea; 55 are open to participants now.

Browse Apnea studies →

Open to participants now

15 of the 85 studies in Apnea with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Apnea studies recruiting now, 9 (23%) set no upper age limit and 27 (68%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 22 Weeks to 32 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Apnea with a site in United States, or all of them as a file.
02

Study summary

This purpose of this study is to reduce or stop apneas and bradycardias in pre-term infants, before they occur using gentle stimulation.

Read the detailed description

This will be a randomized cross-over trial that will use additional ECG leads connected to a novel device and laptop to determine the accuracy and efficacy of an algorithm to predict, detect, and interrupt episodes of bradycardia for two 4-hour periods. There will be a 4-hour period without vibro-tactile stimulation and a 4-hour period with vibro-tactile stimulation when episodes are predicted or detected.

03

Conditions studied

  • Apnea Neonatal
  • Bradycardia Neonatal

Browse trials for

04

Who can participate

Ages eligible
22 Weeks to 32 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented episodes of apnea with bradycardia over the previous 24 hours.
  • Off ventilatory support/NCPAP for > 48 hours prior to study entry
  • Gestational age \< 32 0/7 weeks' gestation at birth
  • Parents/legal guardians have provided consent for enrollment

Exclusion criteria

Exclusion Criteria:

  • a major malformation or a neuromuscular condition that affects respiration or causes apnea, or terminal illness or decision to withhold or limit support.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Virbrotactile stimulation

    Four hours of vibrotactile stimulation via a closed loop device if an apnea or bradycardia episode is predicted or detected.

    Device: Closed-loop Vibro-Tactile Stimulator

  • Sham comparator
    Control

    Four hours of no vibrotactile stimulation via the closed loop device if an apnea or bradycardia episode is predicted or detected.

    Device: Control

Interventions

  • DeviceClosed-loop Vibro-Tactile Stimulator

    Vibro-Tactile stimulation when bradycardia is predicted or predicted.

  • DeviceControl

    Sham closed-loop vibrotactile stimulator

06

What researchers measure

Primary outcomes

  1. Bradycardia <100 beats per minute ≥ 10 seconds

    The frequency of episodes of bradycardia (heart rate less than 100 of ≥ 10 seconds) in either study arm during the study period.

    Time frame: 4-hours on either intervention.

Secondary outcomes

  1. Bradycardia <60 beats per minute ≥ 5 seconds

    The frequency of episodes of bradycardia (heart rate \<60 beats per minute ≥ 5 seconds) in either study arm during the study period.

    Time frame: 4 hours in either intervention.

  2. Bradycardia <60 beats per minute ≥ 10 seconds

    The frequency of episodes of bradycardia (heart rate \<60 beats per minute ≥ 10 seconds) in either study arm during the study period.

    Time frame: 4 hours on either intervention.

  3. Bradycardia <80 beats per minute ≥ 5 seconds

    The frequency of episodes of bradycardia (heart rate \<80 beats per minute ≥ 5 seconds) in either study arm during the study period.

    Time frame: 4 hours on either intervention.

  4. Bradycardia <80 beats per minute ≥ 10 seconds

    The frequency of episodes of bradycardia (heart rate \<80 beats per minute ≥ 10 seconds) in either study arm during the study period.

    Time frame: 4 hours on either intervention.

  5. Proportion of time with Bradycardia < 100 beats per minute

    The total proportion of time with bradycardia during the study period on either intervention with a heartrate of \<100 beats per minute.

    Time frame: 4 hours on either intervention.

  6. Hypoxemia <85% for ≥ 5 seconds

    The frequency of episodes of hypoxemia (oxygen saturations \<85% for ≥ 5 seconds) in either study arm during the study period.

    Time frame: 4 hours on either intervention.

  7. Hypoxemia <85% for ≥ 10 seconds

    The frequency of episodes of hypoxemia (oxygen saturations \<85% for ≥ 10 seconds) in either study arm during the study period.

    Time frame: 4 hours on either intervention.

  8. Hypoxemia <90% for ≥ 5 seconds

    The frequency of episodes of hypoxemia (oxygen saturations \<90% for ≥ 5 seconds) in either study arm during the study period.

    Time frame: 4 hours on either intervention.

  9. Hypoxemia <90% for ≥ 10 seconds

    The frequency of episodes of hypoxemia (oxygen saturations \<90% for ≥ 10 seconds) in either study arm during the study period.

    Time frame: 4 hours on either intervention.

  10. Hypoxemia <80% for ≥ 5 seconds

    The frequency of episodes of hypoxemia (oxygen saturations \<80% for ≥ 5 seconds) in either study arm during the study period.

    Time frame: 4 hours on either intervention.

  11. Hypoxemia <80% for ≥ 10 seconds

    The frequency of episodes of hypoxemia (oxygen saturations \<80% for ≥ 10 seconds) in either study arm during the study period.

    Time frame: 4 hours on either intervention.

  12. Proportion of time with hypoxemia < 90%

    The total proportion of time with oxygen saturations \<90% during the study period on either intervention.

    Time frame: 4 hours on either intervention.

  13. Bradycardia prediction time

    The number of seconds ahead of routine patient monitors at which the device algorithm predicted bradycardia in either group.

    Time frame: 4 hours on either intervention.

  14. Bradycardia prediction accuracy

    The area under the curve for the true prediction rate over the false alarm rate in the control group.

    Time frame: 4 hours on sham control.

  15. Proportion of time with hypoxemia < 85%

    The total proportion of time with oxygen saturations \<85% during the study period on either intervention.

    Time frame: 4 hours on either intervention.

07

Study locations

1 of 1 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35209, United States
    Recruiting
    • Rachel L Benz Clinical Research Nurse Manager, MSN · Contactrlbenz@uabmc.edu · 205-934-2184
    • Kimberly M. Armstead Clinical Research Coordinator III, B.S. · Contactkarmstead@uabmc.edu · 205-934-0095
    • Colm P. Travers, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data will be made available upon publication through a data use agreement to researchers who provide a methodologically sound proposal for use in achieving the goals of the approved proposal. Proposals should be submitted to cptravers@uabmc.edu.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.

Of 69 non-industry interventional studies with no phase under Apnea, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 15 months is below that.

Counting every sponsor, half of 78 studies reached it within 17 months; a quarter within 8 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Feb 28, 2025
StartActual
Sep 29, 2026
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2028was Dec 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
University of Alabama at Birmingham is now Recruiting
Oct 2, 2026
Start date
Sep 1, 2026→Sep 29, 2026 (actual)
Oct 2, 2026
Primary completion
Dec 31, 2026→Dec 31, 2027
Oct 2, 2026
Study completion
Dec 31, 2027→Dec 31, 2028
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Recruiting
    University of Alabama at Birmingham is now Recruiting
    Start date Sep 1, 2026→Sep 29, 2026 (now actual)
    Primary completion Dec 31, 2026→Dec 31, 2027
    Study completion Dec 31, 2027→Dec 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06852053
Responsible party
Colm Travers (Associate Professor of Pediatrics, University of Alabama at Birmingham) — Principal investigator
First posted
Feb 28, 2025
Start date
Sep 29, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Rachel L. Benz, Clinical Research Nurse Manager, MSN
Contact
rlbenz@uabmc.edu
205-934-2184
Kimberly M. Armstead Clinical Research Coordinator III, B.S.
Contact
karmstead@uabmc.edu
205-934-0095
Colm P. Travers Associate Professor of Pediatrics, M.D.
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion